FeesSafety
Pluang+

Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Company Fundamentals
19 Nov 2026, 03:00 WIB
The Motley Fool Team
View Source
Bullish
Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb increased its full-year 2026 earnings guidance following a 12% revenue growth in its growth portfolio to $7.7 billion, driven by eight medicines each generating over $1 billion annually. The company is offsetting losses from patent expirations with new drug launches and late-stage clinical trial successes, including FDA clearance of a multiple myeloma therapy. Cost-saving initiatives are supporting reinvestments and shareholder returns, despite expected revenue declines from European patent expirations in 2027. Management remains confident in long-term growth fueled by pipeline advancements and manufacturing investments.

Following Bristol-Myers Squibb's optimistic 2026 earnings guidance update, the stock is currently trading at USD 59.81 on Pluang as of Nov 19, 2026 03:11 WIB, down 2.51% for the day. Despite the recent dip, the company maintains a dividend yield of 4.11%, with a market cap of $125.40 billion. Pluang investors have shown a strong selling interest, with 100% of order activity leaning towards selling.

More News (BMY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App